-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Enterprise News] According to data, from January to May this year, the actual use of foreign capital in the country was 562 billion yuan, a year-on-year increase of 1
It can be seen from the data that China's steady growth in attracting foreign investment remains unchanged, and multinational companies are still optimistic about the Chinese mark.
Recently, it was reported that Sumitomo Pharmaceutical .
, L.
, a large Japanese pharmaceutical company, established a new investment company "Sumitomo Pharmaceutical Investment (China) .
, L.
" in Huangpu, which will contribute positively to the high-quality development of the big health industry in Huangpu Distri.
Statistics show that Japan's Sumitomo Pharmaceutical .
, L.
was established in 1984 by the merger of the pharmaceutical divisions of Sumitomo Chemical and Inabata Sang.
The company entered the Chinese market as early as the 1990s and developed the Chinese market as a It is one of the most important market operation bases in the wor.
In the process of developing the Chinese market, the pharmaceutical company has introduced international production technology into China, providing patients with high-level products and medical solutions in the fields of central nervous system, anti-infection, cardiovascular and digestive tract, bringing many benefits to patien.
Gosp.
Through years of rapid development, the company's sales and market share in China have continued to grow, which has brought its performance growth moment.
Not long ago, PharmExec (American Pharmaceutical Managers Magazine) announced the top 50 list of global pharmaceutical companies in 202Sumitomo Pharmaceutical ranks 36th with sales of US$602 billion and R&D investment of US$869 million, which shows its streng.
It is reported that the company decided to set up a new investment company in Chi.
The main purpose is to integrate the equity structure, strengthen the integrated compliance operation, and manage and strengthen its business in Chi.
Currently in China, Sumitomo Pharma has a large production base in Suzhou, and has established branches in Beijing, Shanghai and Guangzhou, and has established a research and development system and a nationwide marketing network that can serve the national mark.
It is worth mentioning that in April this year, Sumitomo Pharma (Suzhou) .
, L.
also announced some changes: starting from April 1, Sumitomo Pharma will use a new brand identity and image together with Sumitomo Pharma .
, L.
, which means the mission of the group: to constantly pursue self-reform, meet challenges, and quickly realize innovation, so that people around the world can live a healthier life and better themselv.
To fulfill this commitment, Sumitomo Pharma Group will actively engage in three research focus areas of Psychiatry & Neurology, Oncology, Regenerative Medicine & Cell Therapy, as well as Infectious Diseases and other emerging health frontie.
At the same time, Sumitomo Pharma (Suzhou) .
, L.
appointed Yilong Ling as President of Sumitomo Pharma, effective April 1, 202According to public information, Lingwei Yilong has 20 years of experience in the management of multinational pharmaceutical companies and is well versed in the Chinese pharmaceutical mark.
From 2019 to 2021, he served as President of Sumitomo Pharma Asia Pacific and achieved outstanding resul.
Previously, he served as chairman and general manager of Astellas Pharmaceuticals (China) .
,L.
Under the guidance of the spiritual concept of "Beginning with Responsibility and Building with Trust", Sumitomo Pharma has an attitude of being responsible to patients and society, and loves to maintain human health, so that friendship will be permanent in China! Moving into the future, the company stated that it will continue to adhere to the "patient-centered" concept, protect the health of Chinese patients with innovative medical care, and contribute to the "Healthy China 2030" strategic go.
Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to anyone
It can be seen from the data that China's steady growth in attracting foreign investment remains unchanged, and multinational companies are still optimistic about the Chinese mark.
Recently, it was reported that Sumitomo Pharmaceutical .
, L.
, a large Japanese pharmaceutical company, established a new investment company "Sumitomo Pharmaceutical Investment (China) .
, L.
" in Huangpu, which will contribute positively to the high-quality development of the big health industry in Huangpu Distri.
Statistics show that Japan's Sumitomo Pharmaceutical .
, L.
was established in 1984 by the merger of the pharmaceutical divisions of Sumitomo Chemical and Inabata Sang.
The company entered the Chinese market as early as the 1990s and developed the Chinese market as a It is one of the most important market operation bases in the wor.
In the process of developing the Chinese market, the pharmaceutical company has introduced international production technology into China, providing patients with high-level products and medical solutions in the fields of central nervous system, anti-infection, cardiovascular and digestive tract, bringing many benefits to patien.
Gosp.
Through years of rapid development, the company's sales and market share in China have continued to grow, which has brought its performance growth moment.
Not long ago, PharmExec (American Pharmaceutical Managers Magazine) announced the top 50 list of global pharmaceutical companies in 202Sumitomo Pharmaceutical ranks 36th with sales of US$602 billion and R&D investment of US$869 million, which shows its streng.
It is reported that the company decided to set up a new investment company in Chi.
The main purpose is to integrate the equity structure, strengthen the integrated compliance operation, and manage and strengthen its business in Chi.
Currently in China, Sumitomo Pharma has a large production base in Suzhou, and has established branches in Beijing, Shanghai and Guangzhou, and has established a research and development system and a nationwide marketing network that can serve the national mark.
It is worth mentioning that in April this year, Sumitomo Pharma (Suzhou) .
, L.
also announced some changes: starting from April 1, Sumitomo Pharma will use a new brand identity and image together with Sumitomo Pharma .
, L.
, which means the mission of the group: to constantly pursue self-reform, meet challenges, and quickly realize innovation, so that people around the world can live a healthier life and better themselv.
To fulfill this commitment, Sumitomo Pharma Group will actively engage in three research focus areas of Psychiatry & Neurology, Oncology, Regenerative Medicine & Cell Therapy, as well as Infectious Diseases and other emerging health frontie.
At the same time, Sumitomo Pharma (Suzhou) .
, L.
appointed Yilong Ling as President of Sumitomo Pharma, effective April 1, 202According to public information, Lingwei Yilong has 20 years of experience in the management of multinational pharmaceutical companies and is well versed in the Chinese pharmaceutical mark.
From 2019 to 2021, he served as President of Sumitomo Pharma Asia Pacific and achieved outstanding resul.
Previously, he served as chairman and general manager of Astellas Pharmaceuticals (China) .
,L.
Under the guidance of the spiritual concept of "Beginning with Responsibility and Building with Trust", Sumitomo Pharma has an attitude of being responsible to patients and society, and loves to maintain human health, so that friendship will be permanent in China! Moving into the future, the company stated that it will continue to adhere to the "patient-centered" concept, protect the health of Chinese patients with innovative medical care, and contribute to the "Healthy China 2030" strategic go.
Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to anyone
